Document is current
Any future updates will be listed below
-
Authors
Zhao, Yilu https://orcid.org/0000-0003-3219-3188
Fu, Zhao https://orcid.org/0000-0003-4780-6602
Barnett, Eric J.
Wang, Ning https://orcid.org/0000-0001-5384-5283
Zhang, Kangfuxi
Gao, Xuping https://orcid.org/0000-0003-3813-2036
Zheng, Xiangyu
Tian, Junbin
Zhang, Hui
Ding, XueTong
Li, Shaoxian
Li, Shuyu https://orcid.org/0000-0002-3459-6821
Cao, Qingjiu
Chang, Suhua https://orcid.org/0000-0001-7465-3985
Wang, Yufeng
Faraone, Stephen V.
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81471381)
National Natural Science Foundation of China (81671358)
National Natural Science Foundation of China (31871259)
Beijing Municipal Science and Technology Commission (Z181100001518005))
- License Information
-
More Information
Article History
Received: 17 March 2024
Revised: 6 December 2024
Accepted: 17 January 2025
First Online: 7 February 2025
Competing interests
: In the past year, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support from Aardvark, Aardwolf, AIMH, Akili, Atentiv, Axsome, Genomind, Ironshore, Johnson & Johnson/Kenvue, Kanjo, KemPharm/Corium, Noven, Otsuka, Sky Therapeutics, Sandoz, Supernus, Tris, and Vallon. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. He also receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health, Oxford University Press: Schizophrenia: The Facts and Elsevier: ADHD: Non-Pharmacologic Interventions. He is Program Director of and . Dr. Faraone’s research is supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement 965381; NIH/NIMH grants U01AR076092, R01MH116037, 1R01NS128535, R01MH131685, 1R01MH130899, U01MH135970, and Supernus Pharmaceuticals. His continuing medical education programs are supported by The Upstate Foundation, Corium Pharmaceuticals, Tris Pharmaceuticals and Supernus Pharmaceuticals.
: The study was approved by the Institutional Review Board of the Peking University Health Science Center (2010–19; 2018–21). After complete description of the study to the subjects, written informed consent was obtained from parents of the ADHD individuals. The current research was registered in ClinicalTrials.gov (NCT01065259). All methods were performed in accordance with the relevant guidelines and regulations.
